Proactive Investors - Run By Investors For Investors

IQ-AI surges as Imaging Biometrics signs business development deal with CorTechs Labs

The medical software and services group said the agreement would provide its products with “extended and immediate” sales representation in the US and other international markets
Handshake
IQ-AI said IB’s products would complement those of CorTechs, which specialises in assessing neurological conditions

IQ-AI Limited’s (LON:IQAI) shares surged on Wednesday after its subsidiary, Imaging Biometrics (IB), signed a non-exclusive business development and sales deal with brain analysis firm CorTechs Labs.

The medical software and services group said the agreement would provide its products with “extended and immediate” sales representation in the US and other international markets, while CorTech would add IB’s software and exclusive algorithms to its portfolio.

READ: IQ-AI’s Imaging Biometrics featured in American Journal of Neuro Radiology

The product suite includes IB’s StoneChecker software, which helps analyse kidney stones, as well as IB Neuro which provides tumour biology data and the IB Delta Suite which helps clinicians distinguish tumour progression from treatment effects.

IQ-AI said IB’s products would complement those of CorTechs, which specialises in assessing neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.

David Smith, IB’s chief executive, said the deal meant IQ-AI’s products would have “direct sales representation worldwide” for the first time, and that the firm was “very excited” about the shared revenue potential of the agreement.

“CorTechs Labs has a well established and rapidly growing sales and marketing team who can introduce IB's portfolio to their existing and new clients”, he added.

In mid-afternoon the shares were 8.3% higher at 1.3p.

--Adds share price--

View full IQAI profile View Profile

IQ-AI Limited Timeline

Related Articles

H&T
May 21 2019
"The group's performance over the past three years demonstrates the continuing success of our strategy to access more customers and markets," said chief executive John Nichols.
drainpipes
May 23 2019
Company is looking for more acquisitions after integration of Metro Rod
medical imaging graphic
Thu
Here we take a closer look at the imaging and diagnostics firm IQ-AI

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use